Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG
2020-12-10 12:51
Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals
2020-12-09 07:49
Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma
2020-11-18 07:39
Kazia Executes Agreement To Commence GBM Agile Pivotal Study
2020-10-16 07:30
Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma
2020-09-22 09:21
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
2020-08-24 09:14
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma
2020-08-20 08:35
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
2020-08-07 08:30
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
2020-06-22 12:39
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
2020-06-01 08:45
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
2020-04-07 20:00
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
2019-12-11 08:41
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
2019-11-25 07:00
Kazia Raises A$4.0 Million to Progress R&D Programs
2019-10-28 10:16
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
2019-09-13 20:00
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
2019-09-12 21:10
Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
2019-07-22 09:08
Kazia calls for greater awareness of the deadliest brain cancer in the US
2019-07-17 20:00
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
2019-05-20 11:41
Kazia calls for greater awareness of the deadliest gynecological cancer in the US
2019-05-08 20:00
1
2
3
4